INO-5412

**INO-5412** is an investigational, single-vial plasmid DNA cancer immunotherapy developed by INOVIO for glioblastoma. It combines **INO-5401**, which encodes the tumor-associated antigens human telomerase reverse transcriptase, prostate-specific membrane antigen, and Wilms tumor protein, with **INO-9012**, a plasmid encoding interleukin-12 as a T-cell immune activator. It is administered by intramuscular injection followed by electroporation and is being evaluated in the Phase 2 INSIGhT adaptive platform trial in combination with the separately administered PD-1/CTLA-4 bispecific antibody cadonilimab. ([ir.inovio.com](https://ir.inovio.com/news/news-details/2026/INOVIO-and-Akeso-Announce-Clinical-Collaboration-to-Advance-Novel-Combination-Therapy-for-Glioblastoma-GBM/default.aspx))

Other names

INO-5401 + INO-9012